相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Seizures as a Potential Complication of Treatment With Simeprevir and Sofosbuvir
Gaurav Syal et al.
AMERICAN JOURNAL OF THERAPEUTICS (2016)
Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection
C. Bunchorntavakul et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Tablets for Hepatitis C Virus Genotype 1 Infection
Olga M. Klibanov et al.
ANNALS OF PHARMACOTHERAPY (2015)
Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug Interactions
Timothy Eley et al.
CLINICAL PHARMACOKINETICS (2015)
The Role of Organic Transporters in Pharmacokinetics and Nephrotoxicity of Newer Antiviral Therapies for HIV and Hepatitis C
Donald Mitema et al.
CURRENT DRUG METABOLISM (2015)
Simeprevir: A Review of Its Use in Patients with Chronic Hepatitis C Virus Infection
Mark Sanford
DRUGS (2015)
Interaction Between Amiodarone and Sofosbuvir-based Treatment for Hepatitis C Virus Infection: Potential Mechanisms and Lessons to be Learned
David J. Back et al.
GASTROENTEROLOGY (2015)
Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation
Michael Charlton et al.
GASTROENTEROLOGY (2015)
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
Michael Charlton et al.
GASTROENTEROLOGY (2015)
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials
Saleh A. Alqahtani et al.
HEPATOLOGY (2015)
All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study
David R. Nelson et al.
HEPATOLOGY (2015)
Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant
Surakit Pungpapong et al.
HEPATOLOGY (2015)
Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis
Varun Saxena et al.
HEPATOLOGY (2015)
Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1 A Randomized Trial
Mark S. Sulkowski et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
C-SURFER: GRAZOPREVIR PLUS ELBASVIR IN TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION AND CHRONIC KIDNEY DISEASE
D. Roth et al.
JOURNAL OF HEPATOLOGY (2015)
SAFETY AND EFFICACY OF SHORT-DURATION TREATMENT WITH GS-9857 COMBINED WITH SOFOSBUVIR/GS-5816 IN TREATMENT-NAIVE AND DAA-EXPERIENCED GENOTYPE 1 PATIENTS WITH AND WITHOUT CIRRHOSIS
E. J. Gane et al.
JOURNAL OF HEPATOLOGY (2015)
DACLATASVIR, SOFOSBUVIR, AND RIBAVIRIN COMBINATION FOR HCV PATIENTS WITH ADVANCED CIRRHOSIS OR POSTTRANSPLANT RECURRENCE: PHASE 3 ALLY-1 STUDY
F. Poordad et al.
JOURNAL OF HEPATOLOGY (2015)
Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir
Rajeev M. Menon et al.
JOURNAL OF HEPATOLOGY (2015)
EASL Recommendations on Treatment of Hepatitis C 2015
JOURNAL OF HEPATOLOGY (2015)
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial
Eric Lawitz et al.
LANCET (2015)
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial
Christophe Hezode et al.
LANCET (2015)
Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial
K. Rajender Reddy et al.
LANCET INFECTIOUS DISEASES (2015)
Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy
Saeed H. Al Marzooqi et al.
LIVER INTERNATIONAL (2015)
Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting
Christoph Hoener Zu Siederdissen et al.
LIVER INTERNATIONAL (2015)
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1
Susanna Naggie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Simeprevir with peginterferon and ribavirin induced interstitial pneumonitis: First case report
Katsuyoshi Tamaki et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Ritonavir-boosted protease inhibitor based therapy: a new strategy in chronic hepatitis C therapy
Samuel W. Brayer et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2015)
New era for management of chronic hepatitis C virus using direct antiviral agents: A review
Tamer Elbaz et al.
JOURNAL OF ADVANCED RESEARCH (2015)
Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study
Hiromitsu Kumada et al.
HEPATOLOGY RESEARCH (2015)
Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST-1, QUEST-2 and PROMISE studies
J. Scott et al.
JOURNAL OF VIRAL HEPATITIS (2015)
Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection
R. S. Koff
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scores
Albader Albarmawi et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Hepatitis C virus therapy in the direct acting antiviral era
Mitchell L. Shiffman
CURRENT OPINION IN GASTROENTEROLOGY (2014)
Sofosbuvir: A Review of its Use in Patients with Chronic Hepatitis C
Gillian M. Keating
DRUGS (2014)
Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial
Stefan Zeuzem et al.
GASTROENTEROLOGY (2014)
Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial
Xavier Forns et al.
GASTROENTEROLOGY (2014)
ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection
Pietro Andreone et al.
GASTROENTEROLOGY (2014)
Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection
Hiromitsu Kumada et al.
HEPATOLOGY (2014)
Hepatitis C Direct-acting Antiviral Agents Changing the Paradigm of Hepatitis C Treatment in HIV-infected Patients
Valerie Martel-Laferriere et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2014)
Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1-infected patients in Japan: the DRAGON study
Norio Hayashi et al.
JOURNAL OF GASTROENTEROLOGY (2014)
Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies
Namiki Izumi et al.
JOURNAL OF GASTROENTEROLOGY (2014)
Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders
Anna S. Lok et al.
JOURNAL OF HEPATOLOGY (2014)
Simeprevir with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial
Norio Hayashi et al.
JOURNAL OF HEPATOLOGY (2014)
Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus Infection
John O. Link et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor
Asa Rosenquist et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
Michael Manns et al.
LANCET (2014)
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
Eric Lawitz et al.
LANCET (2014)
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
Ira M. Jacobson et al.
LANCET (2014)
Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial
Michael Manns et al.
LANCET (2014)
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
Eric Lawitz et al.
LANCET (2014)
Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2
Alastair J. O'Brien et al.
NATURE MEDICINE (2014)
An Interferon-free Antiviral Regimen for HCV after Liver Transplantation
Paul Y. Kwo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Retreatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin
Stefan Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Treatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin
Jordan J. Feld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Nezam Afdhal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Nezam Afdhal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
Stefan Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
Kris V. Kowdley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
ABT-450/r-Ombitasvir and Dasabuvir with or without Ribavirin for HCV
Peter Ferenci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
Mark S. Sulkowski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
Fred Poordad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Hepatitis C virus NS5A inhibitors and drug resistance mutations
Shingo Nakamoto et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection
Ivan Gentile et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2014)
Mechanisms Underlying Benign and Reversible Unconjugated Hyperbilirubinemia Observed with Faldaprevir Administration in Hepatitis C Virus Patients
Rucha S. Sane et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Benefit-risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir
John N. Gaetano
DRUG HEALTHCARE AND PATIENT SAFETY (2014)
Pharmacokinetic Interactions Between the Hepatitis C Virus Protease Inhibitor Boceprevir and Ritonavir-Boosted HIV-1 Protease Inhibitors Atazanavir, Darunavir, and Lopinavir
Ellen G. J. Hulskotte et al.
CLINICAL INFECTIOUS DISEASES (2013)
The importance of drug-drug interactions in the DAA era
David Back et al.
DIGESTIVE AND LIVER DISEASE (2013)
Simeprevir for the treatment of chronic hepatitis C
David M. You et al.
EXPERT OPINION ON PHARMACOTHERAPY (2013)
Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection-A Randomized Trial
Fred Poordad et al.
GASTROENTEROLOGY (2013)
Once-Daily Simeprevir (TMC435) With Pegylated Interferon and Ribavirin in Treatment-Naive Genotype 1 Hepatitis C: The Randomized PILLAR Study
Michael W. Fried et al.
HEPATOLOGY (2013)
PHARMACOKINETICS OF SIMEPREVIR (TMC435) IN VOLUNTEERS WITH MODERATE OR SEVERE HEPATIC IMPAIRMENT
S. Ouwerkerk-Mahadevan et al.
JOURNAL OF HEPATOLOGY (2013)
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890
Christophe Hezode et al.
JOURNAL OF HEPATOLOGY (2013)
Drug-drug interactions during antiviral therapy for chronic hepatitis C
Jennifer J. Kiser et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2013)
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Ira M. Jacobson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
Edward J. Gane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Eric Lawitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants
Vincenzo Summa et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives
Christoph Welsch et al.
GUT (2012)
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders
Kazuaki Chayama et al.
HEPATOLOGY (2012)
New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials
L. Y. Lee et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2012)
THE EFFECT OF RENAL IMPAIRMENT AND END STAGE RENAL DISEASE ON THE SINGLE-DOSE PHARMACOKINETICS OF PSI-7977
M. T. Cornpropst et al.
JOURNAL OF HEPATOLOGY (2012)
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial
Stanislas Pol et al.
LANCET INFECTIOUS DISEASES (2012)
Hepatitis C Variability, Patterns of Resistance, and Impact on Therapy
Cristina Simona Strahotin et al.
ADVANCES IN VIROLOGY (2012)
An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases
Marc G. Ghany et al.
HEPATOLOGY (2011)
Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection
Kenneth E. Sherman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Drug Interactions with New and Investigational Antiretrovirals
Herta M. Crauwels et al.
CLINICAL PHARMACOKINETICS (2010)
Ribavirin Improves Early Responses to Peginterferon Through Improved Interferon Signaling
Jordan J. Feld et al.
GASTROENTEROLOGY (2010)
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
Paul Y. Kwo et al.
LANCET (2010)
Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy
Thierry Poynard et al.
GASTROENTEROLOGY (2009)
Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection
John G. McHutchison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors
Ann D. Kwong et al.
CURRENT OPINION IN PHARMACOLOGY (2008)
Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease
RB Perni et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Role for interferon-γ in the immunomodulatory activity of human bone marrow mesenchymal stem cells
Mauro Krampera et al.
STEM CELLS (2006)
Mechanism of action of interferon and ribavirin in treatment of hepatitis C
JJ Feld et al.
NATURE (2005)
Unravelling hepatitis C virus replication from genome to function
BD Lindenbach et al.
NATURE (2005)
Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF
K Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Non-nucleoside analogue inhibitors bind to an allosteric site on HCVNS5B polymerase - Crystal structures and mechanism of inhibition
MT Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRP) NS5B and modulates RNA-dependent RNA polymerase activity
Y Shirota et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Drug-induced cutaneous photosensitivity - Incidence, mechanism, prevention and management
DE Moore
DRUG SAFETY (2002)
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
MP Manns et al.
LANCET (2001)
Medical progress: Hepatitis C virus infection.
GM Lauer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
A novel mechanism to ensure terminal initiation by hepatitis C virus NS5B polymerase
Z Hong et al.
VIROLOGY (2001)
CYP3A activity in European American and Japanese men using midazolam as an in vivo probe
T Tateishi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
分享论文
